Skip to main content Skip to section navigation Skip to footer
  • ViraxImmuneTM
  • Pipeline
  • Clinician hub
  • News
  • About
  • Investors
  • ViraxImmuneTM
  • Pipeline
  • Clinician hub
  • News
  • About
  • Investors

Partner With Us

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 16, 2024 7:30am EDT

Virax Biolabs to Participate at ESCMID Global 2024

Mar 15, 2024 4:30pm EDT

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Dec 21, 2023 7:30am EST

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Dec 18, 2023 7:30am EST

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Dec 14, 2023 7:30am EST

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Sep 12, 2023 7:30am EDT

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 01, 2023 7:30am EDT

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Aug 03, 2023 7:30am EDT

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Jul 18, 2023 7:30am EDT

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Jun 14, 2023 7:30am EDT

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

BioCity Glasgow
Bo’Ness Road, Newhouse
Lanarkshire,
ML1 5UH,
United Kingdom

Explore

  • ViraxImmune TM
  • Pipeline
  • Clinician hub

Company

  • About
  • News
  • Partner with us
  • Investors

Legal

  • Terms and Conditions
  • Privacy policy

Looking for Research Solutions?

Visit our research site for information on ImmuneSelect research-use products, custom laboratory services, and scientific capabilities.

Go to Virax Research

© All Rights Reserved, Virax Biolabs 2026

Facebook Instagram Linkedin X-twitter